Self-replicating RNA (srRNA) technology, in comparison to mRNA vaccines, has shown dose-sparing by approximately 10-fold and more durable immune responses. However, no improvements are observed in the adverse events profile. Here, we develop an srRNA vac
This study examined short-to-medium term safety of COVID-19 vaccines among adults aged ≥65 years using the Canadian National Vaccine Safety Network active safety surveillance data. Both vaccinated and unvaccinated older adult participants recruited from seven provinces and territories were included in ...
INTERPRETATION: This first-ever demonstration in human beings shows that a prophylactic mRNA-based candidate vaccine can induce boostable functional antibodies against a viral antigen when administered with a needle-free device, although not when injected by a needle-syringe. The vaccine was generally ...
The exposure of interest was receipt of an mRNA COVID-19 vaccine, from 1 to 21 days after dose 1 or dose 2, of vaccine-eligible members of 8 US health plans that participated in the VSD. The expected number of events was determined by a concurrent comparison control group, primarily ...
Rabies is a lethal disease caused by the rabies virus (RABV), which causes acute neurological infections in mammals, including human beings. We previously reported that an mRNA vaccine (LVRNA001) encoding the rabies virus’s glycoprotein induced strong p
mRNA technology, used by mRNA COVID-19 vaccines including COMIRNATY, has the potential to streamline vaccine development. This allows for a timely response to FDA-recommended updates to the vaccine for emerging strains of the virus that causes COVID-19. ...
One technology being applied in this development is the use of self-amplifying mRNA (sa-mRNA) that allows host cells to make copies of the vaccine mRNA, increasing the amount of protein produced with lower doses of administered mRNA12,13,14,15. Preclinical studies have shown sa-mRNA vaccines...
mRNA vaccines represent a promising alternative to conventional vaccine approaches because of their high potency, capacity for rapid development, and potential for low-cost manufacturing and safe administration. However, their application has been restricted by the instability and inefficientin vivodeli...
of individuals and groups, many of whom describe themselves asvaccine risk-aware. By dismissing these concerns as “antivaccine activism” or “hesitancy,” Hotez fails to address the complexity and diversity of the movement. There is a spectrum of positions in the community he casts as “anti...
(Gamaleya National Research Centre for Epidemiology and Microbiology) showing an efficacy of 91·6% (85·6–95·2); mRNA-1273 SARS-CoV-2 vaccine (Moderna) showing an efficacy of 94·1% (89·3–96·8), and BNT162b2 mRNA COVID-19 vaccine (Pfizer–BioNTech) showing an efficacy of 95% ...